Genmab A/S
GNMSF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.58B
Close$
$55.76
90.1% downside
Current Fair Value
90.1% downsideOvervalued by 90.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $34.58 Billion |
|---|---|
| Enterprise Value | $38.37 Billion |
| Earnings per Share | $16.04 |
| Beta | 0.69 |
| Outstanding Shares | 61,336,032 |
Return
| Return on Equity | 16.02% |
|---|---|
| Return on Assets | 7.62% |
| Return on Invested Capital | 23.38% |
Valuation & Multiples
| P/E Ratio | 30.96 |
|---|---|
| PEG | -315.25 |
| Price to Sales | 3.55 |
| Price to Book Ratio | 5.81 |
| Enterprise Value to Revenue | 3.92 |
| Enterprise Value to EBIT | 14.43 |
| Enterprise Value to Net Income | 40 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.89 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$3.56
Consensus analyst estimateRevenue Estimate
$1.12 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$3.49
Consensus analyst estimateRevenue Estimate
$1.20 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Genmab
3,029 employees
CEO: Jan van de Winkel
Genmab A/S, established in 1999 and headquartered in Copenhagen, Denmark, is a biotechnology firm specializing in the development of antibody therapeutics for cancer and various other medical conditions, primarily operating from its Dani...